Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Morphic Holding stock

Own Morphic Holding stock in just a few minutes.

Fact checked

Morphic Holding, Inc is a biotechnology business based in the US. Morphic Holding shares (MORF) are listed on the NASDAQ and all prices are listed in US Dollars. Morphic Holding employs 87 staff and has a trailing 12-month revenue of around USD$38.7 million.

How to buy shares in Morphic Holding

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Morphic Holding. Find the stock by name or ticker symbol: MORF. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Morphic Holding reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Morphic Holding, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Morphic Holding. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Morphic Holding share price

Use our graph to track the performance of MORF stocks over time.

Morphic Holding shares at a glance

Information last updated 2021-02-24.
52-week rangeUSD$9.9 - USD$41
50-day moving average USD$33.7415
200-day moving average USD$29.8662
Wall St. target priceUSD$45
PE ratio 6.9814
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-17.629

Buy Morphic Holding shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Gold/Commodities
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, Cryptocurrency
Stocks & ETFs: $1/contract to open, $0 to close, $10 max/leg
Futures: $2.50/contract to open, $0 to close
Get 100 shares of stock (worth $1 to $6 a share)
Open and fund a new cash or margin account with $2,000+
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
$0 for US stocks
Stocks, Options, ETFs
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Morphic Holding stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Morphic Holding under- or over-valued?

Valuing Morphic Holding stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Morphic Holding's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Morphic Holding's P/E ratio

Morphic Holding's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 7x. In other words, Morphic Holding shares trade at around 7x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Morphic Holding financials

Revenue TTM USD$38.7 million
Gross profit TTM USD$-36,755,000
Return on assets TTM -12.92%
Return on equity TTM -32.51%
Profit margin -121.63%
Book value $4.227
Market capitalisation USD$1.1 billion

TTM: trailing 12 months

Shorting Morphic Holding shares

There are currently 1.8 million Morphic Holding shares held short by investors – that's known as Morphic Holding's "short interest". This figure is 29.2% up from 1.4 million last month.

There are a few different ways that this level of interest in shorting Morphic Holding shares can be evaluated.

Morphic Holding's "short interest ratio" (SIR)

Morphic Holding's "short interest ratio" (SIR) is the quantity of Morphic Holding shares currently shorted divided by the average quantity of Morphic Holding shares traded daily (recently around 155404.71698113). Morphic Holding's SIR currently stands at 11.66. In other words for every 100,000 Morphic Holding shares traded daily on the market, roughly 11660 shares are currently held short.

However Morphic Holding's short interest can also be evaluated against the total number of Morphic Holding shares, or, against the total number of tradable Morphic Holding shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Morphic Holding's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Morphic Holding shares in existence, roughly 60 shares are currently held short) or 0.1484% of the tradable shares (for every 100,000 tradable Morphic Holding shares, roughly 148 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Morphic Holding.

Find out more about how you can short Morphic Holding stock.

Morphic Holding share dividends

We're not expecting Morphic Holding to pay a dividend over the next 12 months.

Morphic Holding overview

Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidates in clinical development are MORF-720, a selective oral avß6 specific integrin inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC); and MORF-057, a a4ß7 specific integrin inhibitor for the treatment of inflammatory bowel disease (IBD). The company is also developing MR ß6 #2, a selective avß6 specific integrin inhibitor to treat IPF and PSC; and avß1 integrin for the treatment of fibrosis. Morphic Holding, Inc. has a research collaboration with Engitix Ltd for the identification of Morphic integrin technology amenable targets in fibrostenotic IBD; a collaboration agreement with Schrödinger, LLC for integrin targets; and a license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. It also has collaboration agreements with AbbVie Biotechnology Ltd and Janssen Pharmaceuticals, Inc. to discover or develop integrin-based therapeutics; and drug discovery research collaboration with HitGen Inc. to identify small molecule leads against targets specified by the company. The company was founded in 2014 and is based in Waltham, Massachusetts.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site